Markets:

Overview

News

Currencies

International

Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

63.87 +2.41 (+3.92%)

Streaming Delayed Price Updated: 9:54 AM EDT, Aug 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

1 Oversold Stock Primed to Rebound and 2 That Underwhelm

December 15, 2025

The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling...

Via StockStory

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

December 08, 2025

BioMarin Pharmaceutical (BMRN) presents a compelling value investment case, trading at a significant discount to its biotech peers while showing strong profitability, financial health, and growth...

Via Chartmill

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗

December 03, 2025

One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.

Via The Motley Fool

Topics Regulatory Compliance

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗

December 03, 2025

PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down.

Via The Motley Fool

Topics Regulatory Compliance

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

December 03, 2025

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?

Via The Motley Fool

Topics Regulatory Compliance

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...

Via MarketMinute

2 Reasons to Like BMRN and 1 to Stay Skeptical

November 24, 2025

BioMarin Pharmaceutical currently trades at $55.56 per share and has shown little upside over the past six months, posting a small loss of 4.4%. The stock also fell short of the S&P 500’s 11.5% gain...

Via StockStory

Topics Stocks

Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks

November 23, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q3, starting with BioMarin...

Via StockStory

Topics Artificial Intelligence

AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Via StockStory

Topics Economy Government World Trade

BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings?

November 20, 2025

Over the past six months, BioMarin Pharmaceutical’s stock price fell to $51.76. Shareholders have lost 11.5% of their capital, which is disappointing considering the S&P 500 has climbed by 13.7%. This...

Via StockStory

Topics Stocks

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗

November 20, 2025

Shares in the biotech company have surged on news of a big pharma takeover.

Via The Motley Fool

The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market

November 14, 2025

The global financial markets are in the midst of a profound transformation, driven by an accelerating wave of technological advancements. From the intricate algorithms of Artificial Intelligence to the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

1 Safe-and-Steady Stock on Our Watchlist and 2 We Question

November 12, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

Via StockStory

Topics Artificial Intelligence Stocks

3 Cash-Producing Stocks with Promising Prospects

November 09, 2025

Free cash flow is one of the most reliable indicators of financial durability. These businesses not only generate cash but reinvest intelligently to sustain momentum.

Via StockStory

This Zimmer Biomet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

November 06, 2025

Via Benzinga

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

November 05, 2025

BioMarin presents a strong value investment case with low valuation multiples, robust profitability, and a healthy balance sheet, all while showing solid growth potential.

Via Chartmill

The 5 Most Interesting Analyst Questions From BioMarin Pharmaceutical’s Q3 Earnings Call

November 03, 2025

BioMarin Pharmaceutical’s third quarter results reflected steady top-line growth, with management highlighting enzyme therapies and the Skeletal Conditions business as main contributors. CEO Alexander...

Via StockStory

Topics Earnings

Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday ↗

October 28, 2025

Although the company recorded higher sales overall, it's decided to divest one of its products.

Via The Motley Fool

Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today

October 28, 2025

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 4.5% in the morning session after the company reported third-quarter earnings, which featured a significant earnings miss but a...

Via StockStory

Topics Earnings Economy Government

Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings ↗

October 28, 2025

Via Benzinga

BMRN Q3 Deep Dive: Product Expansion and Portfolio Shifts Define Outlook

October 28, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.1% year on year to $776.1 million. The company’s outlook for the full year was...

Via StockStory

BioMarin (BMRN) Q3 2025 Earnings Call Transcript ↗

October 27, 2025

BioMarin (BMRN) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Reports Mixed Q3 2025 Results with Revenue Growth but Earnings Miss ↗

October 27, 2025

BioMarin's Q3 2025 results show mixed performance with revenue growth but a significant earnings miss, while the company raises its full-year outlook.

Via Chartmill

Topics Earnings

BioMarin Pharmaceutical (NASDAQ:BMRN) Posts Q3 Sales In Line With Estimates

October 27, 2025

Via StockStory

Earnings Scheduled For October 27, 2025 ↗

October 27, 2025

Via Benzinga

BioMarin Pharmaceutical (BMRN) Reports Q3: Everything You Need To Know Ahead Of Earnings

October 25, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results this Monday after market close. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

What to Expect from Biomarin Pharmaceutical's Earnings ↗

October 24, 2025

Via Benzinga

3 of Wall Street’s Favorite Stocks to Target This Week

October 24, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

1 Healthcare Stock Worth Investigating and 2 We Question

October 17, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.